• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Zontivity (vorapaxar)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Zontivity (vorapaxar)

  • Profile

Profile

Contact Information

Contact: WraSer Pharmaceuticals
Website: https://www.zontivity.com/

Currently Enrolling Trials

    Show More

    General Information

    Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist.

    Zontivity is specifically indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).

    Zontivity is supplied as a tablet for oral administration. The recommended dose is one tablet (2.08 mg) orally once daily, with or without food.

    Mechanism of Action

    Zontivity (varapaxar) s a reversible antagonist of the protease-activated receptor-1 (PAR-1) expressed on platelets, but its long half-life makes it effectively irreversible. Vorapaxar inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation in in vitro studies. Vorapaxar does not inhibit platelet aggregation induced by adenosine diphosphate (ADP), collagen or a thromboxane mimetic and does not affect coagulation parameters ex vivo. PAR-1 receptors are also expressed in a wide variety of cell types, including endothelial cells, neurons, and smooth muscle cells, but the pharmacodynamic effects of vorapaxar in these cell types have not been assessed.

    Side Effects

    The most frequently reported side effect associated with the use of Zontivity is bleeding, including life-threatening and fatal bleeding.

    Clinical Trial Results

    The FDA approval of Zontivity was based on TRA 2°P - TIMI 50. TRA 2°P was a multicenter, randomized, double-blind, placebo-controlled study conducted in patients who had evidence or a history of atherosclerosis involving the coronary, cerebral (ischemic stroke), or peripheral vascular systems. Subjects were randomized to receive daily treatment with Zontivity (n=13,225) or placebo (n=13,224) in addition to standard of care. The study’s primary endpoint was the composite of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR). The composite of cardiovascular death, MI, and stroke was assessed as key secondary endpoint. The median follow-up was 2.5 years (up to 4 years). The findings in all randomized patients for the primary efficacy composite endpoint show a 3-year K-M event rate of 11.2% in the Zontivity group compared to 12.4% in the placebo group. The findings for the key secondary efficacy endpoint show a 3-year Kaplan-Meier (K-M) event rate of 9.3% in the Zontivity group compared to 10.5% in placebo group.

    Approval Date: 2014-05-01
    Company Name: WraSer Pharmaceuticals
    Back to Listings

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • MAGI East 2023

      MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

    • Complexity-360x240.png

      Phase 3 Trials Significantly Rising in Complexity, Says CSDD

    • Quality Level Scale

      Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

    • DE&I

      Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing